Aadi Bioscience has entered into a Stock Purchase Agreement with KAKEN Pharmaceutical, selling its subsidiary, including the FYARRO business, for $100 million, which will fund operations into late ...
- Poster Presentation to go Live on October 7, 2021 at 9 a.m. ET and on Demand at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics- LOS ANGELES, Oct. 06 ...
After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses "The data published in JCO highlight the ...
On Thursday, Aadi Bioscience, Inc. (NASDAQ:AADI) entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug ...
MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial ...
Commercial-stage biopharmaceutical company Aadi Bioscience announced that it has entered into a private investment in public equity (PIPE) deal valued at $72.5 million. Aadi, which develops precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results